Thematische Bibliographien / Heart Effect of drugs on

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Bücher
Buchteile
Konferenzberichte
Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Heart Effect of drugs on“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 31. Januar 2023

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Heart Effect of drugs on" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Heart Effect of drugs on"

Farrell, A. P., und M. S. Graham. „Effects of adrenergic drugs on the coronary circulation of Atlantic salmon (Salmo salar)“. Canadian Journal of Zoology 64, Nr. 2 (01.02.1986): 481–84. http://dx.doi.org/10.1139/z86-071.

Der volle Inhalt der Quelle

Annotation:

Spontaneously beating hearts from Atlantic salmon (Salmo salar) were used to examine the adrenergic regulation of the perfused coronary circulation. Excitatory α-adrenoceptors (vasoconstriction) dominated over inhibitory β-adrenoceptors (vasodilatation). Increased heart rate via β-adrenergic stimulation was possible with drug injections into the coronary artery. The heart rate effects followed the vasoactive effect by approximately 2 min.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Rorabaugh, Boyd R., Sarah L. Seeley, Albert D. Bui, Lisanne Sprague und Manoranjan S. D'Souza. „Prenatal methamphetamine differentially alters myocardial sensitivity to ischemic injury in male and female adult hearts“. American Journal of Physiology-Heart and Circulatory Physiology 310, Nr. 4 (15.02.2016): H516—H523. http://dx.doi.org/10.1152/ajpheart.00642.2015.

Der volle Inhalt der Quelle

Annotation:

Methamphetamine is one of the most common illicit drugs abused during pregnancy. The neurological effects of prenatal methamphetamine are well known. However, few studies have investigated the potential effects of prenatal methamphetamine on adult cardiovascular function. Previous work demonstrated that prenatal cocaine exposure increases sensitivity of the adult heart to ischemic injury. Methamphetamine and cocaine have different mechanisms of action, but both drugs exert their effects by increasing dopaminergic and adrenergic receptor stimulation. Thus the goal of this study was to determine whether prenatal methamphetamine also worsens ischemic injury in the adult heart. Pregnant rats were injected with methamphetamine (5 mg·kg−1·day−1) or saline throughout pregnancy. When pups reached 8 wk of age, their hearts were subjected to ischemia and reperfusion by means of a Langendorff isolated heart system. Prenatal methamphetamine had no significant effect on infarct size, preischemic contractile function, or postischemic recovery of contractile function in male hearts. However, methamphetamine-treated female hearts exhibited significantly larger infarcts and significantly elevated end-diastolic pressure during recovery from ischemia. Methamphetamine significantly reduced protein kinase Cε expression and Akt phosphorylation in female hearts but had no effect on these cardioprotective proteins in male hearts. These data indicate that prenatal methamphetamine differentially affects male and female sensitivity to myocardial ischemic injury and alters cardioprotective signaling proteins in the adult heart.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Nordin, Henrik, Anders M. Galløe, Søren D. Ladefoged und Jørn Badskjær. „The effects of propranolol and verapamil on hyperthyroid heart symptoms and function, assessed by systolic time intervals“. Acta Endocrinologica 128, Nr. 4 (April 1993): 297–300. http://dx.doi.org/10.1530/acta.0.1280297.

Der volle Inhalt der Quelle

Annotation:

The effects of acute and chronic administration of propranolol and verapamil on heart rate and systolic time intervals were studied in 10 hyperthyroid patients and 10 normal subjects, both groups without signs of cardiovascular or pulmonary disease. In normal subjects iv propranolol reduced heart rate significantly, and both drugs increased the total electromechanical systole significantly without difference between the drugs. This effect was insignificant when the drugs were given orally. In hyperthyroid patients both drugs reduced heart rate significantly in acute and chronic administration, and no difference between the two drugs was found. Neither drug altered cardiac contractility as assessed by systolic time intervals. These results indicate that the metabolic effects of thyroid hormone on contractility were unaltered and unblocked by the drugs. None of the participants developed signs of heart failure. Verapamil can thus be used as an alternative to propranolol in the treatment of tachycardia in hyperthyroidism.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Haverkamp, W. „Heart rate effects of antimuscarinic drugs“. International Urology and Nephrology 51, Nr. 10 (27.07.2019): 1783–84. http://dx.doi.org/10.1007/s11255-019-02239-6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Frigy, Attila, Márta Germán-Salló, Lehel Máthé und Mónika Szabó. „Vércukorcsökkentő gyógyszerek biztonságossága szívelégtelenségben“. Orvosi Hetilap 158, Nr. 5 (Februar 2017): 163–71. http://dx.doi.org/10.1556/650.2017.30652.

Der volle Inhalt der Quelle

Annotation:

Abstract: The association of diabetes and heart failure is very common, furthermore, the pathophysiology and clinical course of the two entities have many crossing-points. Today, the spectrum of available anti-diabetic drugs is extremely wide, ranging from the classical (insulin, biguanides, sulphonylureas) to the most recent agents (gliptins, gliflozins). The cardiovascular effects of these drugs are multiple, their knowledge is important in the everyday practice, as the use of safe drugs regarding of heart failure is preferred. Our work provides an overview of each class of drugs after the presentation of the mechanism of action and the main representatives, the effects on the cardiovascular system, including those on heart failure will be described, mentioning the results of the most important clinical trials. The available data confirm the beneficial effects of metformin and gliflozins and the harmful effect of thiazolidinediones in heart failure. The other classes of drugs are permitted in heart failure, but it is important to continuously monitor the signs of decompensation. Orv. Hetil., 2017. 158(5), 163–171.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Bakhteev, R. R. „Effect of retabolil on hyperuricemia in chronic heart failure“. Kazan medical journal 68, Nr. 2 (15.04.1987): 102–3. http://dx.doi.org/10.17816/kazmj96023.

Der volle Inhalt der Quelle

Annotation:

Anabolic steroid drugs are widely used in the complex therapy of chronic heart failure. The positive effect of drugs of this group, in particular retabolol, is associated with the normalization of protein metabolism. Therefore, it is of interest to determine the possible effect of retabolol on purine metabolism as a component of protein metabolism, especially at the stage of uric acid formation. The development of hyperuricemic condition in heart failure against the background of treatment with cardiac glycosides and diuretics are reported by V. Е. Anisimov et al.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Girouard, Catherine, Jean-Pierre Grégoire, Paul Poirier und Jocelyne Moisan. „Effect of contraindicated drugs for heart failure on hospitalization among seniors with heart failure“. Medicine 96, Nr. 9 (März 2017): e6239. http://dx.doi.org/10.1097/md.0000000000006239.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Gatzov, Plamen. „New glucose-lowering drugs in patients with heart failure“. Bulgarian Cardiology 27, Nr. 2 (21.07.2021): 60–64. http://dx.doi.org/10.3897/bgcardio.27.e70144.

Der volle Inhalt der Quelle

Annotation:

The cardiovascular diseases are one of the main causes of mortality in the countries of Europe and North America. The heart failure (HF) and diabetes mellitus (DM) are widely spread diseases that become more frequent with the population aging in those regions. The algorithm of HF treatment in the last two decades includes several new medications. The SGLT-2 inhibitors (dapagliﬂ ozin, empagliﬂ ozin and canagloﬂ ozin) are new class anti diabetic medications which have positive effect on cardiovascular complications in patients with and without DB. The main trials using those medications in this group of patients and the most probable mechanisms, responsible for their effects, are the topic of this review.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Fehér, Gergely, und Gabriella Pusch. „Role of antihypertensive drugs in the treatment of migraine“. Orvosi Hetilap 156, Nr. 5 (Februar 2015): 179–85. http://dx.doi.org/10.1556/oh.2015.30056.

Der volle Inhalt der Quelle

Annotation:

The treatment of migraine depends on the frequency, severity and concomitant diseases. There are several specific drugs developed for migraine prevention in addition to the additive antimigraine effects of some other non-specific drugs. The aim of this literature-based review is to summarize the possible antimigraine properties of different antihypertensive agents (beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, etc.) focusing on the possible side effects (avoidance of beta blockers in the absence of heart disease, possible antiparkinson effect of calcium channel blockers, additive effect of drugs modifying the renin-angiotensin system activity, etc.). Current evidence supports the use of angiotensin converting enzyme inhibitors (mainly lisinopril) and angiotensin receptor blockers (mainly candesartan) for long-term migraine prevention and blood pressure control. Long-term beta-blocker treatment should be avoided in the absence of ischemic heart disease due to possible unfavourable cardiovascular effects. Orv. Hetil., 2015, 156(5), 179–185.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Benfey, B. G. „Antifibrillatory effects of α1-adrenoceptor blocking drugs in experimental coronary artery occlusion and reperfusion“. Canadian Journal of Physiology and Pharmacology 71, Nr. 2 (01.02.1993): 103–11. http://dx.doi.org/10.1139/y93-015.

Der volle Inhalt der Quelle

Annotation:

The myocardium of animals and man possesses α1-adrenoceptors in addition to β-adrenoceptors. Ischemia increases sympathetic tone, and ventricular arrhythmias can occur by β- and α1-adrenoceptor stimulation. I believe that α1-adrenoceptor blocking drugs have antifibrillatory effects and will review the data that support this condition. The effect of α1,-adrenoceptor blocking drugs on the incidence of ventricular fibrillation in acute coronary artery occlusion and (or) reperfusion has been determined in 24 studies in conscious and anesthetized dogs and rats, anesthetized cats and pigs, and rat and guinea-pig isolated hearts. The drugs reduced the incidence of fibrillation from 35 to 24% in coronary occlusion and from 61 to 29% in reperfusion.Key words: heart, coronary occlusion, coronary reperfusion, ventricular fibrillation, α1-adrenoceptor blocking drugs.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "Heart Effect of drugs on"

Zeitz, Christopher John. „Acute drug effects on the heart-haemodynamic, pharmacologic and metabolic correlations“. Title page, contents and abstract only, 1999. http://web4.library.adelaide.edu.au/theses/09PH/09phz48.pdf.

Der volle Inhalt der Quelle

Annotation:

Addenda and corrigenda inserted on verso of back end paper. Includes: Publications and communications to learned societies (p. 4-5). Bibliography: leaves 272-286. Examines the acute myocardial uptake of drugs, particularly perindoprilat and enalaprilat in humans. The uptake of these agents is examined, together with the haemodynamic, metabolic and biochemical effects. In particular, the impact of these agents on angiotensin and bradykinin peptides both within the heart and peripherally is described. The acute effects of a range of cardioactive drugs upon the left ventricular force-interval relationship is examined.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Maune, Jerene Mary 1953. „THE EFFECT OF CAFFEINE ON HEART RATE, RHYTHM AND BLOOD PRESSURE“. Thesis, The University of Arizona, 1986. http://hdl.handle.net/10150/276372.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Ramadan, Waile Rushing Ann E. Hartberg W. Keith. „The protective effect of [alpha]-lipoic acid in doxorubicin induced cardiotoxicity in rats“. Waco, Tex. : Baylor University, 2008. http://hdl.handle.net/2104/5218.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Li, Y. M. J. „An in-vivo study of the anti-arrhythmic and electrophysiological effects of amiodarone, lignocaine and penticainide (CM7857) in the rat“. Thesis, De Montfort University, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.233821.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Huang, Yi Fei. „Myocardial pharmacokinetics and pharmacodynamics in the sheep /“. Title page, contents and abstract only, 1991. http://web4.library.adelaide.edu.au/theses/09PH/09phh8742.pdf.

Der volle Inhalt der Quelle

Annotation:

Thesis (Ph. D.)--University of Adelaide, Dept. of Anaesthesia and Intensive Care, 1992.
Accompanying diskette contains data of Chapters 3, 4, 5, 7, 8 and 9 (ASCII). Includes bibliographical references (leaves 177-207).

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Ritchie, Rebecca Helen. „Acute haemodynamic effects of three cardioactive agents: metoprolol, sotalol and milrinone : influence of myocardial content and systolic interval /“. Title page, table of contents and summary only, 1994. http://web4.library.adelaide.edu.au/theses/09PH/09phr611.pdf.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Shubat, Pamela Jane. „Monocrotaline toxicity and pulmonary arteries“. Diss., The University of Arizona, 1988. http://hdl.handle.net/10150/184533.

Der volle Inhalt der Quelle

Annotation:

Monocrotaline is a pyrrolizidine alkaloid found in plants implicated in livestock and human poisoning. Laboratory rats given monocrotaline develop pulmonary hypertension and right heart hypertrophy in the weeks following administration of the chemical. Lung weight increases and right heart hypertrophy correlate with increased pulmonary artery pressure. Rats which consumed monocrotaline drinking water (20 mg/l) for only 4 days developed significant increases in lung and heart weights 14 days after exposure began. This exposure was equivalent to a dose of 15 mg/kg. Other treatment combinations of time (0-10 days exposure) and monocrotaline concentration (5-60 mg/l in drinking water) were tested. The accumulative dose calculated for each of the treatment combinations which produced toxicity was in the range of 15 to 20 mg/kg. Monocrotaline injury appears to be cumulative, but organ weight increases reverse once exposure is stopped. As pulmonary hypertension develops and pulmonary arteries hypertrophy, the force with which isolated pulmonary artery segments contract decreases. This is a loss of efficacy rather than potency to the contracting agents KCl, norepinephrine, and 5-hydroxytryptamine. Relaxation of arteries under conditions of potassium-return (a measure of Na⁺/K⁺ ATPase activity) was also altered by monocrotaline treatment. In vivo monocrotaline treatment had little effect on the force of K⁺-return relaxation. However, the rate at which arteries relaxed was significantly decreased following 4 days ingestion of monocrotaline drinking water (20 mg/l). In vitro ouabain treatment and endothelial injury also decreased the rate of K⁺-return relaxation. Another Na⁺/K⁺ ATPase activity, ⁸⁶Rb⁺ uptake, was decreased following monocrotaline treatment only when 5-hydroxytryptamine was present and only uptake associated with the endothelium was affected. These studies utilized a very low exposure to monocrotaline (4 days ingestion of 20 mg/l monocrotaline drinking water or 15 mg/kg) to produce toxicity in rats. Monocrotaline-induced toxicity measured 20 days after treatment included right heart and lung hypertrophy and decreased contractions of isolated pulmonary arteries. Monocrotaline treatment decreased the rate of Na⁺/K⁺ ATPase-dependent relaxation of isolated pulmonary arteries 4 days after treatment began.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Rossouw, Ellen. „The effect of androgenic anabolic steroids on the susceptibility of the rat heart to ischaemia and reperfusion injury“. Thesis, Stellenbosch : Stellenbosch University, 2002. http://hdl.handle.net/10019.1/53105.

Der volle Inhalt der Quelle

Annotation:

Thesis (MSc)--University of Stellenbosch, 2002.
ENGLISH ABSTRACT: Background: Athletes use androgenic anabolic steroids (AAS) to enhance their physical performance. The abuse of AAS is however associated with a host of side effects including sudden death due to cardiac arrest. The use of AAS leads to myocardial hypertrophy, which possibly makes the heart more prone to ischaemia/reperfusion injury, since it often develops in the absence of proper vasculature development. Chronic AAS use also disrupts myocardial p-adrenoreceptor function and possibly cAMP, signalling in the heart. Drugs increasing cAMP and decreasing cGMP levels in the ischaemic myocardium exacerbate myocardial ischaemia/reperfusion injury. We also know that AAS causes coronary artery disease secondary to the deleterious alteration of lipid profiles by increasing the LOL cholesterol and decreasing the HOLcholesterol levels. AAS treatment may increase systemic TNFa levels by stimulating lymphocyte TNFa secretion that has been implicated in the depression of myocardial function, myocardial hypertrophy and the worsening of ischaemia/reperfsuion injury. Aims: To determine whether chronic AAS treatment in trained and untrained rats influences: 1) heart function and susceptibility to ischaemia/reperfusion injury, 2) myocardial cyclic nucleotide levels (cAMP and cGMP) and 3) myocardial TNFa levels. Material and methods: Male Sprague-Dawley rats (n=100) were divided into 4 groups: sedentary vehicle (placebo) treated group, sedentary AAS treated group, exercise vehicle (placebo) treated group, and exercise AAS treated group. Steroid treated animals received an intramuscular injection of nandrolone laureate (0.375 mg/kg) once a week, for six weeks. Training consisted of swim sessions 6 days a week for 6 weeks. Swim time was incrementally increased up to a maximum of 50 minutes a day. For biometric parameters heart weight and body weight were documented. Hearts were mounted on a l.anqendorff perfusion apparatus and left ventricular developed pressure (LVDP), heart rate (HR) and coronary flow (CF) was monitored. The hearts were subjected to a period of 20 minutes of global ischaemia, followed by 30 minutes of reperfusion. Functional parameters was again monitored and documented. For biochemical analysis, blood was collected for the determination of serum lipid levels and myocardial tissue samples were collected before, during and after ischaemia for the determination of myocardial TNFa, cGMP and cAMP levels and p38 activity. Conclusions: Results obtained would suggest that AAS exacerbate exercise induced myocardial hypertrophy. It also prevents the exercise-induced improvement in cardiac function. AAS use reduces reperfusion function in treated hearts, which may suggest that AAS exacerbates ischaemie and reperfusion injury. Furthermore it was seen that AAS elevates basal (preischaemie) cyclic nucleotide levels and basal (pre-ischaemic) as well as reperfusion TNFa levels. This may also contribute to the exacerbation of ischaemic and reperfusion injury.
AFRIKAANSE OPSOMMING: Agtergrond: Androgeniese anaboliese steroïede (AAS) word dikwels deur atlete gebruik om sportprestasie te verbeter. Die misbruik van AAS het egter talle newe effekte, insluitende skielike dood wat gewoonlik toegeskryf word aan hartaanvalle. Die gebruik van AAS lei onder andere tot miokardiale hipertrofie wat opsigself, as gevolg van ontoereikende vaskulêre ontwikkeling tydens die ontwikkeling van hipertrofie, die hart nog meer vatbaar vir isgemie/herperfusie skade maak. Kroniese AAS toediening versteur miokardiale beta-adtenoresepter funksie en moontlik die tweede boodskapper, sAMP, seintransduksie in die hart. Ons weet ook dat AAS koronêre hartvatsiektes veroorsaak. Laasgenoemde is sekondêr tot die nadelige lipiedprofiel verandering, wat 'n verhoging in LDL-C en 'n verlaging in HDL-C insluit. Middels wat miokardiale sAMP vlakke verhoog en sGMP vlakke in die isgemiese miokardium verlaag, vererger miokardiale isgemie/herperfusie skade. AAS behandeling kan moontlik ook sistemiese TNFa vlakke verhoog deur limfosiet TNFa sekresie te stimuleer. Die verhoogde TNFa vlakke word verbind aan die onderdrukking van miokardiale funksie, miokardiale hipertrofie en die verergering van isgemie/herperfusie skade. Doelwitte: Die doelwitte van die studie was om te bepaal of kroniese AAS toediening in geoefende en ongeoefende rotte 1) hartfunksie en die hart se vatbaarheid vir isgemie/herperfusie skade beïnvloed, 2) miokardiale sikliese nukleotiedvlakke (sAMP en sGMP) beïnvloed en 3) miokardiale TNFa-vlakke beïnvloed. Materiale en metodes: Manlike Sprague-Dawley rotte (n=100) is gebruik en in 4 groepe verdeel: 'n ongeoefende placebo groep (kontrole); 'n ongeoefende steroïedbehandelde groep; 'n geoefende placebo groep (kontrole) en 'n geoefende steroïedbehandelde groep. Steroïed behandelde diere het 'n intramuskulêre nandroloon lauraat inspuiting (0.375 mg/kg) een keer per week vir ses weke ontvang. Die oefenprogram het bestaan uit ses swemsessies 'n week vir ses weke. Die swemtyd is geleidelik weekliks verhoog tot by 'n maksimum tyd 50 min. Die waterbadtemperatuur is tussen 30 - 32 oe gehandhaaf. Vir biometriese parameters is hartgewig en liggaamsgewig genoteer. Harte is op 'n Langendorff perfusie apparaat gemonteer en linker ventrikulêre ontwikkelde druk (LVOD), koronêre vloei (KV) en harttempo (HT) is genoteer. Die harte is vervolgens blootgestel aan 20 minute van globale isgemie gevolg deur 'n 30 minute herperfusieperiode. LVOD, KV en HT is weer eens noteer. Vir biochemiese doeleindes is bloed voor perfusie versamelom serum lipied vlakke te bepaal. Miokardiale weefsel is versamel voor, tydens en na isgemie vir die bepaling van TNFa, cGMP en AMP vlakke asook p38 aktiwiteit. Gevolgtrekkings: Na aanleiding van resultate verkry wil dit voorkom asof die gebruik van steroïde oefeningsgeïnduseerde miokardiale hipertrofie vererger. Dit verhoed ook oefeningsgeïnduseerde verbetering in miokardiale funksie. AAS lei tot 'n verlaagde herperfusiefunksie in behandelde harte, wat dalk mag dui op MS verergering van isgemie en herperfusie skade. Verder was daar ook waargeneem dat MS basale (pre-isgemiese) sikliese nukleotiedvlakke en basale TNFa-vlakke sowel as herperfusie TNFa vlakke verhoog. Die verhoging in TNF-a vlakke mag dus moontlik ook bydra tot die verergering van isgemie- en herperfusieskade.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Leigh, Felicity Suzanne Marshall. „The effects of diet, anorectic drugs and caffeine on various cardiovascular parameters in the rat“. Thesis, University of Bath, 1988. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.382595.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Kalis, Joni Kathryn. „THE EFFECT OF BETA-ADRENERGIC BLOCKADE ON THE DRIFT IN OXYGEN CONSUMPTION WITH PROLONGED EXERCISE“. Thesis, The University of Arizona, 1985. http://hdl.handle.net/10150/292014.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Bücher zum Thema "Heart Effect of drugs on"

H, Opie Lionel, Hrsg. Drugs for the heart. 3. Aufl. Philadelphia: W.B. Saunders Co., 1991.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Denis, Noble, und Earm Yung E, Hrsg. Ionic channels and effect of taurine on the heart. Boston: Kluwer Academic Publishers, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

G, Reves J., und Hall Kenneth D, Hrsg. Common problems in cardiac anesthesia. Chicago: Year Book Medical Publishers, 1987.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

R, Watson Ronald, und Myers Adam K, Hrsg. Alcohol and heart disease. London: Taylor & Francis, 2002.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Droogmans, Steven. Drug-induced valvular heart disease. Hauppauge, N.Y: Nova Science Publishers, 2010.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

I, Simpson Joseph, Hrsg. Anesthesia and the patient with co-existing heart disease. Boston: Little, Brown, 1993.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Gavin, Katherine T. Investigations of cardiovascular [alpha]-adrenoceptor function. Dublin: University College Dublin, 1997.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

M, Muggia Franco, Green Michael D. 1949- und Speyer James L, Hrsg. Cancer treatment and the heart. Baltimore: Johns Hopkins University Press, 1992.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Myers, Adam K., und Ronald R. Watson. Alcohol and heart disease. London: Taylor & Francis, 2003.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

P, Hacker Miles, Lazo John S und Tritton Thomas R, Hrsg. Organ directed toxicities of anticancer drugs: Proceedings of the First International Symposium on the Organ Directed Toxicities of Anticancer Drugs, Burlington, Vermont, USA, June 4-6, 1987. Boston: Nijhoff, 1988.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Buchteile zum Thema "Heart Effect of drugs on"

Schwandt, Peter, Markus G. Donner und Werner O. Richter. „Long-Term Effect of Ldl-Apheresis on Coronary Heart Disease“. In Drugs Affecting Lipid Metabolism, 513–19. Dordrecht: Springer Netherlands, 1996. http://dx.doi.org/10.1007/978-94-009-0311-1_60.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Pugliese, Anna Maria, Elisabetta Coppi, Federica Cherchi und Giancarlo Pepeu. „Cardiovascular Adverse Effects of Psychotropic Drugs“. In Brain and Heart Dynamics, 707–20. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-28008-6_45.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Pugliese, Anna Maria, Elisabetta Coppi, Federica Cherchi und Giancarlo Pepeu. „Cardiovascular Adverse Effects of Psychotropic Drugs“. In Brain and Heart Dynamics, 1–15. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-90305-7_45-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Yang, Charles I., Pravin Taneja und Peter J. Davis. „Sedative Hypnotic and Anesthetic Agents: Their Effect on the Heart“. In Handbook of Pediatric Cardiovascular Drugs, 280–317. London: Springer London, 2008. http://dx.doi.org/10.1007/978-1-84628-953-8_12.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Govoni, Stefano. „Psychiatric and Neurological Effects of Cardiovascular Drugs“. In Brain and Heart Dynamics, 731–44. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-28008-6_46.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Govoni, S. „Psychiatric and Neurological Effects of Cardiovascular Drugs“. In Brain and Heart Dynamics, 1–14. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-90305-7_46-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Erlemeier, H. H., und W. Bleifeld. „Effects of Different Positive Inotropic Drugs in Congestive Heart Failure“. In Heart Failure Mechanisms and Management, 205–10. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-58231-8_21.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Asteggiano, Riccardo. „Physiopathology and Toxic Heart Effects of Chemotherapy Drugs“. In Cardiac Management of Oncology Patients, 23–97. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-15808-2_2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Gupta, Suresh Kumar, Meenu Sharma, Ipseeta Mohanty und Dharamvir S. Arya. „Molecular Basis for the Cardioprotective Effect of Herbal Drugs in Ischemic Heart Disease: An Experimental Study“. In Myocardial Ischemia and Preconditioning, 235–48. Boston, MA: Springer US, 2003. http://dx.doi.org/10.1007/978-1-4615-0355-2_17.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Eriksson, L. O., B. Beermann und M. Kallner. „Aspects of the Effects or NSAID’s on Renal Function in Congestive Heart Failure“. In Non-steroidal Anti-Inflammatory Drugs Basis for Variability in Response, 99–103. Basel: Birkhäuser Basel, 1985. http://dx.doi.org/10.1007/978-3-0348-7720-6_12.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Heart Effect of drugs on"

Serša, Gregor. „CLINICAL APPLICATIONS OF ELECTROCHEMOTHERAPY“. In Symposium with International Participation HEART AND … Akademija nauka i umjetnosti Bosne i Hercegovine, 2019. http://dx.doi.org/10.5644/pi2019.181.01.

Der volle Inhalt der Quelle

Annotation:

Electroporation has several biomedical and industrial applications. The biomedical applications are in the field of drug or gene delivery. Electrochemotherapy utilizes electroporation for the increased delivery of cytotoxic drugs like bleomycin or cisplatin into tumors. The use of electrochemotherapy has spread throughout Europe for the treatment of cutaneous tumors or metastases. It is in the NICE guidelines and is becoming standard ablative technique in treatment of cancer. The technological advancements have also enabled the use of electrochemotherapy for the treatment of deep seated tumors, such as soft tissue or liver tumors. Clinical studies demonstrate good effectiveness on fibrosarcomas, colorectal liver metastases and hepatocellular carcinoma. However, electrochemotherapy is a local treatment that also induces moderate local immune response. This so called “in situ vaccination” induced by electrochemotherapy can be exploited in combined treatment with immune checkpoint inhibitors or electrogene therapy with immunostimulating effect. Therefore, gene electrotransfer of plasmid coding for interleukin 12 (IL-12), in combination with electrochemotherapy could result in transformation of electrochemotherapy from local into systemic treatment. This is also of our current interest, and we are undertaking steps to bring this idea from preclinical into clinical testing.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Moussa, Heba Adel Mohamed Lotfy, Gawaher Saleh Abbas Mahgoub, Mashael Ali H. I. Al-Badr und Huseyin Cagatay Yalcin. „Investigating the Cardiac Effects of Sildenafil loaded Nanoparticles on Heart Failure using the Zebrafish Embryo Model“. In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0217.

Der volle Inhalt der Quelle

Annotation:

Background: Cardiovascular diseases (CVDs) are the first cause of death worldwide. Vasolidator agents are used to relax cardiac muscle, but their extremely short half-lifes limit their effectiveness. Sildenafil is such an agent used to relax the blood vessels muscles and increase the blood flow. The conventional drug can lead to serious problems in patients duo to the systematic drug delivery. Use of Nanomedicine potentially can enhance delivery of this agent while reducing the systematic effect of the drug. Aim: The purpose of the research is to examine the effectiveness sildenafil loaded nanoparticles in rescuing heart failure using zebrafish embryo model. Methods: There will be five experimental groups. The zebrafish will be treated with Aristolochic Acid (AA) at 24 hour per fertilization (hpf) to create the heart injury group. The treatment groups will be heart injury followed by a dose of either Sildenafil or Sildenafil loaded nanoparticles at 36 hpf. Two control groups will be the negative control (exposed to egg water) and vehicle control (exposed to the Dimethylsulfoxide (DMSO)).To evaluate the drug effects on embryo, toxicity assessment (Survival rate, tail flicking and hatching rate), cardiotoxicity assessment and gene expression of heart injury marker via RT-PCR will be conducted. Results: Preliminary findings demonstrate, loading Sildenafil to nanoparticles enhances its effectiveness dramatically. The experiments are ongoing to confirm the results. Conclusion: Nanomedicine is a powerful approach to enhance cardiovascular therapy. Vasodilator drugs in particular will benefit from this improvement as demonstrated with our findings

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Rizqhilmi, Muhammad Faris, Muhammad Ikrar Hermanadi, Muhammad Yusuf, Rani Wardani Hakim, Siti Farida und Erni Hernawati Purwaningsih. „The effect of Centella asiatica ethanolic extract on heart interleukin-10 levels of aged Sprague-Dawley rats“. In THE 6TH BIOMEDICAL ENGINEERING’S RECENT PROGRESS IN BIOMATERIALS, DRUGS DEVELOPMENT, AND MEDICAL DEVICES: Proceedings of the 6th International Symposium of Biomedical Engineering (ISBE) 2021. AIP Publishing, 2022. http://dx.doi.org/10.1063/5.0100545.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Kurnikova, Irina, Shirin Gulova, Tatiana Nikishova, Nikolay Kislyy, Sophia Buturlina und Oksana Demina. „Frequency Indicators of Heart Rate Variability in Assessing the Effectiveness of Antihypertensive Therapy in Patients With Metabolic Disorders“. In Human Interaction and Emerging Technologies (IHIET-AI 2022) Artificial Intelligence and Future Applications. AHFE International, 2022. http://dx.doi.org/10.54941/ahfe100875.

Der volle Inhalt der Quelle

Annotation:

The data of 87 patients with diabetes had presented, allowing identifying the relationship between the initial vegetative status and the effectiveness of antihypertensive drugs according to the analysis of heart rate variability. The effectiveness of the therapy was monitored based on the evaluation of daily ECG and blood pressure monitoring data. The effectiveness of therapy depended on the compensation or decompensation of diabetes in patients with cardiac autonomic neuropathy. In patients with DT1 and cardiac autonomic neuropathy (CAN), unsatisfactory compensation was accompanied by hypersympathicotonia, and pronounced clinical efficacy of moxonidine occurred in 92.7% (38 people) regardless of compensation. Unsatisfactory compensation of type 2 diabetes was accompanied by activation of parasympathetic reactions. It was not only reduced the effectiveness of moxonidine, but in some cases created undesirable effects, such as an increase not only in the total spectrum power (TSP), but also in the ULF spectrum to 42.6 ± 7.1%, which did not allow to consider the level of care provided sufficient. To achieve the effect, combination therapy with antihypertensive drugs of other pharmacological groups was required. Insufficient effectiveness of therapy in patients of this group was associated with pronounced changes in autonomic regulation.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Alkawari, Fatima, Wigdan Ali, Fatiha Benslimane und Huseyin Yalcin. „Investigating the Cardiac effects of New Generation Anti-Diabetic Drug Empagliflozin using Zebrafish Embryo Model“. In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0211.

Der volle Inhalt der Quelle

Annotation:

Type 2 diabetes mellitus (T2DM) affects >16% of adults in Qatar. Newly emerging class of antidiabetic drugs focused on SGLT inhibition were observed to reduce CVDs risks in diabetic patients. Up to date, the mechanism contributing to the CV benefits remains unrevealed. Zebrafish embryos were treated with Aristolochic Acid to induce heart failure then treated with Empagliflozin to determine its beneficial effect. Furthermore the expression of SGLT1 & 2 were determined in the hearts of zebrafish. SGLT2 was expressed more then SGLT1 in the heart and whole embryo. Empa significantly improved the zebrafish embryo'scardiachealthafterinductionofheartfailure.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Haddad, Batoul, Zainab El-hashmi, Huseyin Yalcin, Fatiha Benslimane und Hana A. Hussain. „Investigating the Efficacy of Natural Blood Glucose Lowering Compounds in the Prevention of Congenital Heart Defects during Maternal Diabetes using the Chick Embryo“. In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0195.

Der volle Inhalt der Quelle

Annotation:

Diabetes is a metabolic disorder that is characterized by hyperglycemia. Although there are several drugs available for diabetes, patients tend to follow natural remedies. However, the use of these natural remedies lacks scientific evidence of its effect. Therefore, the aim of this project was to first identify the histological changes of the developing heart in a hyperglycemic environments. Secondly, test the efficacy of selected natural compounds in lowering blood glucose levels and to assess its gene expression changes.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

McGoron, Anthony J., und Alicia Fernandez-Fernandez. „Development of a Multiple Indicator Dilution Technique Using Fluorescent Dyes to Measure Cardiac Capillary Permeability“. In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192955.

Der volle Inhalt der Quelle

Annotation:

Anthracyclines are widely-used drugs for the treatment of cancer. Although these drugs are effective in reducing or containing tumor progress, their long-term use is limited by toxicity effects. A special area of concern is related to the toxic effects that these drugs have on the myocardial tissue, including interstitial edema, fibrosis, degeneration of myocardial cells, and cardiac dilatation, among others. The end result is an overall impairment in cardiac function that limits the use of these agents [1,2]. This damage in heart function can be life-threatening, and it causes special concern in patients with prior cardiac dysfunction, as well as in children [2]. As a result of these disadvantages, there is a trend in current research to develop anthracycline derivatives or modified formulations with reduced cardiotoxic effects, as well as to learn more of the mechanisms that mediate this cardiac toxicity. Our long-term goal is to measure changes in capillary endothelium permeability in the heart after administration of anthracyclines which may contribute to the overall deterioration in function observed after chronic treatment with this medication. The goal of this project was to develop a sensitive, non-radioactive technique to measure capillary permeability in experimental animal models. This technique could then be applied in future studies of anthracycline cardiotoxicity.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Al-Ansari, Dana E., Nura A. Mohamed, Isra Marei, Huseyin Yalcin und Haissam Abou-Saleh. „Assessment of Metal Organic Framework as Potential Drug Carriers in Cardiovascular Diseases“. In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0127.

Der volle Inhalt der Quelle

Annotation:

Background: Cardiovascular diseases (CVDs) are considered the major cause of death worldwide. Therapeutic delivery to the cardiovascular system may play an important role in the successful treatment of a variety of CVDs, including atherosclerosis, ischemic-reperfusion injury, and microvascular diseases. Despite their clinical benefits, current therapeutic drugs are hindered by their short half-life and systemic side effects. This limitation could be overcome using controlled drug release with the potential for targeted drug delivery using a nanomedicine approach. In the current study, we have assessed the use of a highly porous nano-sized preparation of iron-based Metal-organic Framework (MOF) commonly referred to as MIL-89 as potential drug carriers in the cardiovascular system. Aims: To assess the effect of MOFs on the viability and cytotoxicity of human vascular cells and the cellular uptake in vitro, and the organ-system toxicity of MOF in vivo using the Zebrafish model. Methods: Human pulmonary endothelial cells (HPAECs) and pulmonary smooth muscle cells (HPASMCs) were treated with variable concentrations of MOFs. The viability, cytotoxicity and anti-inflammatory effects were measured using AlamarBlue, LDH assay and ELISA. The cellular uptake of MOFs were assessed using light, confocal, and transmission electron microscopes and EDS analysis. Moreover, Zebrafish embryos were cultured and treated with MOFs-nanoparticles at 0 hours post fertilization (hpf) followed by different organ-specific assays at 24, 48, and 72 hpf. Results: Although MOFs affect the viability at high concentrations, it does not cause any significant cytotoxicity on HPAECs and HPASMCs. Interestingly, MOFs were shown to have an anti-inflammatory effect. Microscopic images showed an increased (concentration-dependent) cellular uptake of MOFs and transfer to daughter cells in both cell types. Moreover, the in vivo study showed that high concentrations of MOFs delay zebrafish embryos hatching and cause heart deformation, which is currently investigated using cardiotoxicity markers. Conclusion: MOFs is a promising nanoparticle prototypes for drug delivery in the cardiovascular system with high cellular uptake and anti-inflammatory effects. Further investigations of MOFs, including diseased models and drug- loaded formulation is required.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Da Silva, Alberto Vianna Dias, und Vaninha Vieira. „BBAware - A Context-Aware Mobile and Wearable Architecture for Monitoring Beta-Blocked Cardiac Patients“. In VIII Simpósio Brasileiro de Computação Ubíqua e Pervasiva. Sociedade Brasileira de Computação - SBC, 2020. http://dx.doi.org/10.5753/sbcup.2016.9444.

Der volle Inhalt der Quelle

Annotation:

Beta-blockade drugs are still in use as treatment option to lower heart rate, to improve cardiac function, and to reduce cardiovascular events. Patients who use beta-blockers usually surpass a therapeutic test full of collateral effects to adapt their organisms. Furthermore, these patients with a baseline heart rate above 70 beats per minute have a significantly higher risk of all cardiovascular events. Context-aware healthcare field arises as an alternative to monitor patients constantly. This paper introduces the Beta-Blocked Aware (BBAware) project, a pervasive solution, that uses the concepts of ubiquitous healthcare in order to help patients under beta-blockade treatments.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Kumar, A., J. Fareed, W. H. Wehrmacher, D. Hoppensteadt, O. Ulutin und J. M. Walenga. „ENDOTHELIAL FUNCTION MODULATION AND CONTROL OF VASCULAR AND THROMBOTIC DISORDERS: EXPERIMENTAL RESULTS WITH A POLYDEOXY RIBONUCLEOTIDE AGENT DEFIBROTIDE“. In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643149.

Der volle Inhalt der Quelle

Annotation:

Numerous approaches with single and multiple drugs modulating protease cascade, platelet function and blood viscosity and to reduce blood lipids to manage thrombotic processes have been tried. Defibrotide, a polydeoxyribonucleotide, (Mr =17,000) offers a new approach to vascular and related thrombotic processes as it acts via modulation of endothelial cell function. We have used a primate model (Macaca mulatta) to study the endogenous action of this agent after the oral (10-25 mg/kg) and intravenous (5-10 mg/kg) administration. This agent produced no effect on clotting tests and ex vivo laboratory findings but rather it elevated the t-PA (antigen and functional), protein C (antigen and functional), prostacyclin and decreased thromboxane, 01.2-antiplasmin (functional) and t-PA inhibitor (functional) in both studies. These observations suggest that Defibrotide modulates endothelial function. Hepatic isolation in rabbits totally blocked the antithrombotic actions of Defibrotide suggesting that this agent is converted into an active product endogenously. Pretreatment of Defibrotide with nucleases also resulted in a complete loss of its actions. Defibrotide produced dose dependent antithrombotic actions in animal models (rabbit venous stasis and rat vena caval ligation) after either intravenous or oral administration. Blood pressure, heart rate, respiration and kidney function were not altered by it. No effect on bleeding time was noted in any studies. Upon oral administration this drug produced pharmacologic action after 2 hours whereas after intravenous administration, the action peaked at 30 minutes. Defibrotide exhibited cytoprotective effects towards endothelial lining of the vascular smooth muscles characterized by microscopic studies. In summary Defibrotide is an endothelial support agent whose multicomponent actions are primarily mediated via the physical and functional modulation of the endothelial cells in the vascular system.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Heart Effect of drugs on"

Wu, Xiaoqi, Jisen Zhao, Maoxia Fan und Dongo Guo. Quality of Evidence Supporting the Effects of Xinmailong injection in Heart Failure: An Overview of Systematic Reviews and Meta-Analyses. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Oktober 2022. http://dx.doi.org/10.37766/inplasy2022.10.0023.

Der volle Inhalt der Quelle

Annotation:

Review question / Objective: 2.1.1 type of research SRs/MAs of RCT (randomized controlled trial) of Xinmailong injection for the treatment of heart failure. 2.1.2 Subject investigated All included patients met internationally recognized diagnostic criteria for heart failure.There are no limitations on age, gender, ethnicity, time of onset, source of cases and language of publication. 2.1.3 Type of Intervention The control group was treated with conventional basic Western medicine recommended by the guidelines related to heart failure[1, 11], including antiplatelet drugs, anticoagulants, vasodilators, beta-blockers,ACEI (angiotensin-converting enzyme inhibitors), lipid-lowering drugs, and diuretic agents. and other drug treatment. The intervention group was given Xinmailong injection on the basis of the control group.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Black, Sandra, Paul Devereux und Kjell Salvanes. Losing Heart? The Effect of Job Displacement on Health. Cambridge, MA: National Bureau of Economic Research, Dezember 2012. http://dx.doi.org/10.3386/w18660.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Lichtenberg, Frank. The Effect of New Drugs on Mortality from Rare Diseases and HIV. Cambridge, MA: National Bureau of Economic Research, Dezember 2001. http://dx.doi.org/10.3386/w8677.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Treadwell, Jonathan R., James T. Reston, Benjamin Rouse, Joann Fontanarosa, Neha Patel und Nikhil K. Mull. Automated-Entry Patient-Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes. Agency for Healthcare Research and Quality (AHRQ), März 2021. http://dx.doi.org/10.23970/ahrqepctb38.

Der volle Inhalt der Quelle

Annotation:

Background. Automated-entry consumer devices that collect and transmit patient-generated health data (PGHD) are being evaluated as potential tools to aid in the management of chronic diseases. The need exists to evaluate the evidence regarding consumer PGHD technologies, particularly for devices that have not gone through Food and Drug Administration evaluation. Purpose. To summarize the research related to automated-entry consumer health technologies that provide PGHD for the prevention or management of 11 chronic diseases. Methods. The project scope was determined through discussions with Key Informants. We searched MEDLINE and EMBASE (via EMBASE.com), In-Process MEDLINE and PubMed unique content (via PubMed.gov), and the Cochrane Database of Systematic Reviews for systematic reviews or controlled trials. We also searched ClinicalTrials.gov for ongoing studies. We assessed risk of bias and extracted data on health outcomes, surrogate outcomes, usability, sustainability, cost-effectiveness outcomes (quantifying the tradeoffs between health effects and cost), process outcomes, and other characteristics related to PGHD technologies. For isolated effects on health outcomes, we classified the results in one of four categories: (1) likely no effect, (2) unclear, (3) possible positive effect, or (4) likely positive effect. When we categorized the data as “unclear” based solely on health outcomes, we then examined and classified surrogate outcomes for that particular clinical condition. Findings. We identified 114 unique studies that met inclusion criteria. The largest number of studies addressed patients with hypertension (51 studies) and obesity (43 studies). Eighty-four trials used a single PGHD device, 23 used 2 PGHD devices, and the other 7 used 3 or more PGHD devices. Pedometers, blood pressure (BP) monitors, and scales were commonly used in the same studies. Overall, we found a “possible positive effect” of PGHD interventions on health outcomes for coronary artery disease, heart failure, and asthma. For obesity, we rated the health outcomes as unclear, and the surrogate outcomes (body mass index/weight) as likely no effect. For hypertension, we rated the health outcomes as unclear, and the surrogate outcomes (systolic BP/diastolic BP) as possible positive effect. For cardiac arrhythmias or conduction abnormalities we rated the health outcomes as unclear and the surrogate outcome (time to arrhythmia detection) as likely positive effect. The findings were “unclear” regarding PGHD interventions for diabetes prevention, sleep apnea, stroke, Parkinson’s disease, and chronic obstructive pulmonary disease. Most studies did not report harms related to PGHD interventions; the relatively few harms reported were minor and transient, with event rates usually comparable to harms in the control groups. Few studies reported cost-effectiveness analyses, and only for PGHD interventions for hypertension, coronary artery disease, and chronic obstructive pulmonary disease; the findings were variable across different chronic conditions and devices. Patient adherence to PGHD interventions was highly variable across studies, but patient acceptance/satisfaction and usability was generally fair to good. However, device engineers independently evaluated consumer wearable and handheld BP monitors and considered the user experience to be poor, while their assessment of smartphone-based electrocardiogram monitors found the user experience to be good. Student volunteers involved in device usability testing of the Weight Watchers Online app found it well-designed and relatively easy to use. Implications. Multiple randomized controlled trials (RCTs) have evaluated some PGHD technologies (e.g., pedometers, scales, BP monitors), particularly for obesity and hypertension, but health outcomes were generally underreported. We found evidence suggesting a possible positive effect of PGHD interventions on health outcomes for four chronic conditions. Lack of reporting of health outcomes and insufficient statistical power to assess these outcomes were the main reasons for “unclear” ratings. The majority of studies on PGHD technologies still focus on non-health-related outcomes. Future RCTs should focus on measurement of health outcomes. Furthermore, future RCTs should be designed to isolate the effect of the PGHD intervention from other components in a multicomponent intervention.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Brusseau, Valentin, I. Tauveron, R. Bagheri, U. Ugbolue, V. Magnon, J. B. Bouillon-Minois, V. Navel und F. Dutheil. Effect of hyperthyroidism treatments on heart rate variability: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0062.

Der volle Inhalt der Quelle

Annotation:

Review question / Objective: The reversibility of HRV abnormalities in hyperthyroidism remains contradictory. The purpose of the study is to conduct a systematic review and meta-analysis on the effect of antithyroid treatments on HRV in hyperthyroidism. Population: Untreated hyperthyroid patients Intervention: Antithyroid treatment Control: Controls without hyperthyroidism Outcomes: Reversibility of heart rate variability abnormalities in hyperthyroidism Study design: Systematic review. Information sources: All studies that addressed the effect of hyperthyroidism treatment on HRV were reviewed. Studies were searched electronically through the major article databases (PubMed, Cochrane Library, Embase, and Google Scholar) with the following keywords: ("hyperthyroidism" OR "hyperthyroid") AND ("heart rate variability" OR "HRV") until April 4, 2022.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Chou, Roger, Jesse Wagner, Azrah Y. Ahmed, Ian Blazina, Erika Brodt, David I. Buckley, Tamara P. Cheney et al. Treatments for Acute Pain: A Systematic Review. Agency for Healthcare Research and Quality (AHRQ), Dezember 2020. http://dx.doi.org/10.23970/ahrqepccer240.

Der volle Inhalt der Quelle

Annotation:

Objectives. To evaluate the effectiveness and comparative effectiveness of opioid, nonopioid pharmacologic, and nonpharmacologic therapy in patients with specific types of acute pain, including effects on pain, function, quality of life, adverse events, and long-term use of opioids. Data sources. Electronic databases (Ovid® MEDLINE®, PsycINFO®, Embase®, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews) to August 2020, reference lists, and a Federal Register notice. Review methods. Using predefined criteria and dual review, we selected randomized controlled trials (RCTs) of outpatient therapies for eight acute pain conditions: low back pain, neck pain, other musculoskeletal pain, neuropathic pain, postoperative pain following discharge, dental pain (surgical or nonsurgical), pain due to kidney stones, and pain due to sickle cell disease. Meta-analyses were conducted on pharmacologic therapy for dental pain and kidney stone pain, and likelihood of repeat or rescue medication use and adverse events. The magnitude of effects was classified as small, moderate, or large using previously defined criteria, and strength of evidence was assessed. Results. One hundred eighty-three RCTs on the comparative effectiveness of therapies for acute pain were included. Opioid therapy was probably less effective than nonsteroidal anti-inflammatory drugs (NSAIDs) for surgical dental pain and kidney stones, and might be similarly effective as NSAIDs for low back pain. Opioids and NSAIDs were more effective than acetaminophen for surgical dental pain, but opioids were less effective than acetaminophen for kidney stone pain. For postoperative pain, opioids were associated with increased likelihood of repeat or rescue analgesic use, but effects on pain intensity were inconsistent. Being prescribed an opioid for acute low back pain or postoperative pain was associated with increased likelihood of use of opioids at long-term followup versus not being prescribed, based on observational studies. Heat therapy was probably effective for acute low back pain, spinal manipulation might be effective for acute back pain with radiculopathy, acupressure might be effective for acute musculoskeletal pain, an opioid might be effective for acute neuropathic pain, massage might be effective for some types of postoperative pain, and a cervical collar or exercise might be effective for acute neck pain with radiculopathy. Most studies had methodological limitations. Effect sizes were primarily small to moderate for pain, the most commonly evaluated outcome. Opioids were associated with increased risk of short-term adverse events versus NSAIDs or acetaminophen, including any adverse event, nausea, dizziness, and somnolence. Serious adverse events were uncommon for all interventions, but studies were not designed to assess risk of overdose, opioid use disorder, or long-term harms. Evidence on how benefits or harms varied in subgroups was lacking. Conclusions. Opioid therapy was associated with decreased or similar effectiveness as an NSAID for some acute pain conditions, but with increased risk of short-term adverse events. Evidence on nonpharmacological therapies was limited, but heat therapy, spinal manipulation, massage, acupuncture, acupressure, a cervical collar, and exercise were effective for specific acute pain conditions. Research is needed to determine the comparative effectiveness of therapies for sickle cell pain, acute neuropathic pain, neck pain, and management of postoperative pain following discharge; effects of therapies for acute pain on non-pain outcomes; effects of therapies on long-term outcomes, including long-term opioid use; and how benefits and harms of therapies vary in subgroups.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Crosland, Richard D. Effect of Drugs on the Lethality in Mice of the Venoms and Neurotoxins from Sundry Snakes. Fort Belvoir, VA: Defense Technical Information Center, Juli 1990. http://dx.doi.org/10.21236/ada228245.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Georgitsis, Micheal. The Effect of Lymph Sac Pressure on Lymph Heart Pressure Development in the Toad Bufo Marinus. Portland State University Library, Januar 2000. http://dx.doi.org/10.15760/etd.7232.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Zhang, Bin, Ming Zhang, Cao-Jie Lu, Li-Zhi Liu, Chen Jiang und Ming-Jin Zhu. Effect of Znic Supplementation on Patients with Chronic Heart Failure: A systematic Review and Meta Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Januar 2022. http://dx.doi.org/10.37766/inplasy2022.1.0100.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Lleras-Muney, Adriana, und Frank Lichtenberg. The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs. Cambridge, MA: National Bureau of Economic Research, September 2002. http://dx.doi.org/10.3386/w9185.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!